Abstract: An image construction method and system for a heating area is provided. The method includes: obtaining an initial image according to a heating structure diagram and a building structure diagram of the heating area; segmenting the initial image according to heating attribute of the heating area to obtain a plurality of segmentation sub-graphs; performing first collection on a surface temperature of a heating pipeline according to pre-deployed surface devices corresponding to the segmentation sub-graphs, and setting first heating labels corresponding to the segmentation sub-graphs, and meanwhile, performing second collection on a regional temperature of a sub-area of the heating pipeline being located according to a pre-deployed monitoring device corresponding to the segmentation sub-graphs, and setting second heating labels; performing position and temperature analysis on a label setting result of each of the segmentation sub-graphs to obtain a heating image of the heating area.

Abstract: A molecular marker combination linked to quantitative traits of tea plant (+)-catechin content, including a SNP site 1, a SNP site 2, a SNP site 3, a SNP site 4, a SNP site 5, a SNP site 6, a SNP site 7 and a SNP site 8, which are located in tea genomes Scaffold4239:309117, Scaffold3614: 66549, Scaffold349: 3413816, Scaffold1989: 2316385, Scaffold451: 940283, Scaffold3727:442660, Scaffold115:803980 and Scaffold920:281727, respectively, and genotypes thereof are extremely significantly correlated with the (+)-catechin content is provided. A detection method for detecting each site, and one or more molecular marker site is used to evaluate the tea plant (+)-catechin content.

Abstract: Provided are a salt form and a crystal form of a pyrazole substituted imidazo[1,2-a]quinoxaline derivative, and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I), and a preparation method therefor and the use thereof in the preparation of drugs related to dual inhibitors of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2).

Abstract: The MnZn ferrite material includes principal components and auxiliary components, where the principal components include: 52.5 mol % to 53.8 mol % of Fe2O3, 8.8 mol % to 12 mol % of ZnO, and the balance of MnO; the auxiliary components include: 0.35 wt % to 0.5 wt % of Co2O3, 0.03 wt % to 0.08 wt % of CaSiO3, 0.01 wt % to 0.04 wt % of Nb2O5, and 0.05 wt % to 0.12 wt % of TiO2 and RE elemental components; the RE elemental components include one or more from the group consisting of 0 wt % to 0.04 wt % of Gd2O3, 0 wt % to 0.02 wt % of Ho2O3, and 0 wt % to 0.03 wt % of Ce2O3; the auxiliary components are all represented by a mass percentage relative to a total mass of the Fe2O3, the MnO, and the ZnO.

Abstract: A class of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2) dual inhibitors, and specifically disclosed are a compound represented by formula (I), a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a Syk and VEGFR2 dual inhibitor related drug.

Abstract: An inflatable model with lighting effects includes a light-transmissive inflatable body, an air supply component for inflating the interior of the light-transmissive inflatable body, and a main light source which emits light from the interior of the light-transmissive inflatable body. The light-transmissive inflatable body is divided into a plurality of decoration areas. Each decoration area is provided with at least one effect light source. According to the present invention, various lighting effect combinations on the inflatable model can be achieved, thus enriching the exhibition effect of the inflatable model. Therefore, the inflatable model in the present invention can attract attention of people more easily and is more suitable for activity meeting places with diversified lighting effect requirements such as Halloween, Christmas, and the like.

Abstract: A benzo five-membered cyclic compound represented by formula (I) or a pharmaceutically acceptable salt thereof has a significant effect in inhibiting the activity of anti-apoptotic Bcl-2 protein.

Abstract: The present application relates to a method for acquiring maximum principal strain or a maximum principal stress status of a vessel wall.

Abstract: This application provides a communications system (100) for automatically selecting an NFC emulation card, which includes an NFC card reader (102) and an electronic device (101). The NFC card reader (102) sends third query information which includes first identification information and a service type of an emulation card. The electronic device (101) determines whether a first emulation card exists. When determining that the first emulation card exists, the electronic device (101) determines whether a second emulation card exists. When determining that the second emulation card exists, the electronic device (101) sends fourth response information which carries second identification information. The NFC card reader (102) sends card selection instruction information. The electronic device (101) receives the card selection instruction information, and sends card selection response information.

Abstract: Provided is a salt of an Syk inhibitor and a crystalline form thereof, and more specifically, provided are 5-fluoro-1-methyl-3-((5-(4-(oxetan-3-yl)piperazine-1)-yl)pyridin-2-yl)amino)-6-(1H-pyrazol-3-yl)quinoline-2(1H)-ketamine hydrochloride, a crystalline form thereof, a preparation method therefor, a pharmaceutical composition thereof and a use thereof. The hydrochloride of the compound represented by formula I and the crystalline form thereof have good salt-forming properties, high stability and low hygroscopicity, have advantages in terms of physical properties, safety and metabolic stability, and have value in prepared medicines.

Abstract: The MnZn ferrite material includes principal components and auxiliary components, where the principal components include: 52.5 mol % to 53.8 mol % of Fe2O3, 8.8 mol % to 12 mol % of ZnO, and the balance of MnO; the auxiliary components include: 0.35 wt % to 0.5 wt % of Co2O3, 0.03 wt % to 0.08 wt % of CaSiO3, 0.01 wt % to 0.04 wt % of Nb2O5, and 0.05 wt % to 0.12 wt % of TiO2 and RE elemental components; the RE elemental components include one or more from the group consisting of 0 wt % to 0.04 wt % of Gd2O3, 0 wt % to 0.02 wt % of HO2O3, and 0 wt % to 0.03 wt % of Ce2O3; the auxiliary components are all represented by a mass percentage relative to a total mass of the Fe2O3, the MnO, and the ZnO.

Abstract: Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.

Abstract: Disclosed is a method for configuring an MSD parallel adder based on ternary logic operators. Five ternary logic operators that satisfy a sufficient condition for MSD addition are used to configure an MSD parallel adder. During the arrangement of a ternary logic operator, any method in the following may be used: each of ternary operators of n bits is reconfigured into a ternary logic operator each time, and reconfiguration is performed five times for implementation; each of ternary operators of n bits is reconfigured into two ternary logic operators having the same input each time, and reconfiguration is performed three times for implementation; each of ternary operators of n bits is reconfigured into five ternary logic operators of the same time, and reconfiguration is performed once for implementation; corresponding unreconfigurable ternary logic operators are used instead for the foregoing reconfiguration process.

Abstract: The present application relates to a method for acquiring maximum principal strain or a maximum principal stress status of a vessel wall.

Abstract: The present application relates to a method for acquiring maximum principal strain or a maximum principal stress status of a vessel wall.

Abstract: The present application relates to a method and system for analyzing blood flow conditions. The method includes: obtaining images at multiple time phases; constructing multiple vascular models corresponding to the multiple time phases; correlating the multiple vascular models; setting boundary conditions of the multiple vascular models respectively based on the result of correlation; and determining condition of blood vessel of the vascular models.

Abstract: Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.